Delving into the Latest Updates on Tridecaptin analogues Oct-His9(Leiden University) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Pseudomonas aeruginosa infection

Inactive Indication-

Originator Organization

University of Leiden

Active Organization

University of Leiden

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Martin, Nathaniel I ; Du, Chao ; Alexander, Francesca M ; Terlouw, Barbara R ; Elsayed, Somayah S ; Willemse, Joost ; Pieren, Michel ; Al Ayed, Karol ; Schill, Julian ; Machushynets, Nataliia V ; Trebosc, Vincent ; van Wezel, Gilles P ; Cochrane, Stephen A ; Buijs, Ned P ; Liles, Mark R ; Medema, Marnix H

The prevalence of multidrug-resistant (MDR) pathogens combined with a decline in antibiotic discovery presents a major challenge for health care. To refill the discovery pipeline, we need to find new ways to uncover new chemical entities. Here, we report the global genome mining-guided discovery of new lipopeptide antibiotics tridecaptin A₅ and tridecaptin D, which exhibit unusual bioactivities within their class. The change in the antibacterial spectrum of Oct-TriA₅ was explained solely by a Phe to Trp substitution as compared to Oct-TriA₁, while Oct-TriD contained 6 substitutions. Metabolomic analysis of producer Paenibacillus sp. JJ-21 validated the predicted amino acid sequence of tridecaptin A₅. Screening of tridecaptin analogues substituted at position 9 identified Oct-His9 as a potent congener with exceptional efficacy against Pseudomonas aeruginosa and reduced hemolytic and cytotoxic properties. Our work highlights the promise of tridecaptin analogues to combat MDR pathogens.

100 Deals associated with Tridecaptin analogues Oct-His9(Leiden University)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pseudomonas aeruginosa infection	Preclinical	Netherlands	University of Leiden	11 Apr 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data